Gabapentin Tablet
Product Images NDC 70518-2842

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-2842). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 600mg 70518 2842 01

Gabapentin 600 mg tablet packaging label showing quantity of 100 tablets. Label includes the NDC number 70518-2842-01, manufacturer as Ascend Labs, LLC, Montvale, NJ, and repackager as RemedyRepack Inc., Indiana, PA. The label notes storage conditions and advises to see package insert for directions, with a caution to keep medication out of children's reach.*

FDA Label Image

Gabapentin 600mg 70518 2842 02

Gabapentin 600 mg oral tablet packaging label displaying the quantity of 1 tablet. The label includes the NDC number 70518-2842-02 and repackager RemedyRepack Inc., Indiana, PA. Directions note to see the package insert, storage conditions (20-25°C), and a caution to keep medication out of reach of children.*

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 600 mg tablet label showing quantity of 28 tablets. The label includes the NDC 70518-2842-00, manufacturer information for Ascend Labs, LLC, and repackaging details by RemedyRepack Inc. It includes usage directions to see package insert and storage instructions. The label also states 'RX ONLY'.*

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) is shown, involving age, weight, and serum creatinine values, with a multiplication adjustment factor for female patients.*

FDA Label Image

Gabapentin Fig1

Line graph comparing mean pain scores over 8 weeks for Gabapentin 3600 mg/day versus placebo. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin group shows a gradual decrease in pain score, while placebo remains relatively constant.*

FDA Label Image

Gabapentin Fig2

A line graph depicting mean pain scores over a 7-week period for patients receiving placebo or gabapentin at 1800 mg/day and 2400 mg/day. The x-axis represents weeks, starting from baseline to week 7, while the y-axis shows the mean pain score ranging from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, showing pain score decreases over time in gabapentin groups compared to placebo.*

FDA Label Image

Gabapentin Fig3

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' showing results from two studies. Study 1 compares placebo (PBO) at 12% and Gabapentin (GBP) 3600 mg at 29%. Study 2 shows placebo at 14%, Gabapentin 1800 mg at 32%, and Gabapentin 2400 mg at 34%. Statistical significance is indicated with p-values less than 0.01 and 0.001 for Gabapentin groups versus placebo.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot graph showing percentage difference on the vertical axis and daily dose in milligrams on the horizontal axis for gabapentin. The graph compares data points from three studies labeled a, b, and c at daily doses of 600, 900, 1200, and 1800 mg, with markers indicating variations in percentage difference among the studies.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure of Gabapentin shown with its molecular framework, including a cyclohexane ring and functional groups attached, consistent with the generic drug Gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.